ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 606,47
-0,73%
Dow Jones
39 023,50
-0,23%
DAX
18 145,00
-0,10%
Brent Oil
84,055
-0,15%
Bitcoin
61 765,94
-0,07%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. NeuBase Therapeutics Inc (NBSE)

  7. NeuBase Therapeutics Inc (NBSE) Actualités

NBSE

NeuBase Therapeutics (NBSE)

NeuBase Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NBSE
DateHeureSourceTitreSymboleSociété
03/06/202422h08Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:NBSENeuBase Therapeutics Inc
31/05/202422h29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
16/05/202416h07Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:NBSENeuBase Therapeutics Inc
05/04/202422h05GlobeNewswire Inc.NeuBase Therapeutics Announces Receipt of Notice from NasdaqNASDAQ:NBSENeuBase Therapeutics Inc
28/12/202312h15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NBSENeuBase Therapeutics Inc
27/11/202315h00GlobeNewswire Inc.Psychemedics Corporation Appoints Daniella Mehalik as VP - FinanceNASDAQ:NBSENeuBase Therapeutics Inc
09/11/202322h11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NBSENeuBase Therapeutics Inc
21/09/202302h42Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:NBSENeuBase Therapeutics Inc
20/09/202323h28Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:NBSENeuBase Therapeutics Inc
18/09/202322h32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBSENeuBase Therapeutics Inc
12/09/202323h20Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:NBSENeuBase Therapeutics Inc
08/09/202313h00GlobeNewswire Inc.NeuBase Therapeutics Issues Statement Regarding Filing By ShareholderNASDAQ:NBSENeuBase Therapeutics Inc
06/09/202316h00PR Newswire (Canada)SYMETRYX CORPORATION ACQUIRES 20% STOCK IN NEUBASENASDAQ:NBSENeuBase Therapeutics Inc
01/09/202320h51Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NBSENeuBase Therapeutics Inc
31/08/202317h50Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:NBSENeuBase Therapeutics Inc
11/08/202312h20Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:NBSENeuBase Therapeutics Inc
11/08/202312h15Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NBSENeuBase Therapeutics Inc
11/08/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NBSENeuBase Therapeutics Inc
01/08/202322h45Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:NBSENeuBase Therapeutics Inc
28/07/202312h03Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:NBSENeuBase Therapeutics Inc
07/07/202322h11Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:NBSENeuBase Therapeutics Inc
30/06/202314h43Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:NBSENeuBase Therapeutics Inc
30/06/202314h42Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NBSENeuBase Therapeutics Inc
30/06/202314h41Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:NBSENeuBase Therapeutics Inc
05/06/202322h06Edgar (US Regulatory)Quarterly Transition Report (10-qt)NASDAQ:NBSENeuBase Therapeutics Inc
22/05/202313h01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NBSENeuBase Therapeutics Inc
11/05/202322h06Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NBSENeuBase Therapeutics Inc
17/03/202321h12Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NBSENeuBase Therapeutics Inc
06/03/202322h23Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:NBSENeuBase Therapeutics Inc
27/01/202318h49Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:NBSENeuBase Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NBSE

Dernières Valeurs Consultées

NYSE
MRK
Merck
EU
BEL20
Bel 20
COIN
BTCUSD
Bitcoin
EU
EN
Bouygues
COIN
ETHUSD
Ethereum
EU
RI
Pernod Ricard
NASDAQ
NVDA
NVIDIA
EU
MC
Lvmh Moet Hennessy Louis...
USI
USTECH100
US Tech 100
EU
BN
Danone
EU
AF
Air FranceKLM
NYSE
MCD
McDonalds
EU
HO
Thales
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés